SCHEMBL5892425

SCHEMBL5892425

COc1ccc(Cl)cc1B1OCC(C)(C)CO1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
GAA P10253 1/20 0.39
CYP2C19 P33261 1/20 0.39
TRPV4 Q9HBA0 1/20 0.37
KMT2A Q03164 5/20 0.37
MEN1 O00255 4/20 0.37
HTR3E A5X5Y0 1/20 0.36
HTR3B O95264 1/20 0.36
HTR3A P46098 1/20 0.36
HTR3D Q70Z44 1/20 0.36
HTR3C Q8WXA8 1/20 0.36
TSHR P16473 3/20 0.35
MAPK1 P28482 2/20 0.35
HSD17B10 Q99714 2/20 0.35
CASP1 P29466 1/20 0.35
LMNA P02545 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
HPGD P15428 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15304198 0.83 ACHE (0.43) ALDH1A1CYP3A4GAACYP2C19KMT2A
SCHEMBL2658949 0.80 ICMT (0.30)
SCHEMBL5892464 0.80 EGFR (0.47) ALDH1A1TRPV4KMT2AMEN1HTR3E
SCHEMBL13639298 0.78 SNCA (0.33) ALDH1A1KMT2AMEN1HTR3EHTR3B
SCHEMBL5892427 0.78 HTR3E (0.48) ALDH1A1TRPV4HTR3EHTR3BHTR3A
SCHEMBL17940744 0.78 CA1 (0.40) ALDH1A1GAATSHRMAPK1TDP1
SCHEMBL2723790 0.77 TDP1 (0.49) ALDH1A1CYP3A4CYP2C19KMT2AMEN1
SCHEMBL2416029 0.76 SNCA (0.42) ALDH1A1CYP1A2CYP3A4GAACYP2C19
SCHEMBL7163811 0.75 NPC1 (0.34) ALDH1A1TSHRKDM4ERAB9ASNCA
SCHEMBL9941695 0.75 VCAM1 (0.36) ALDH1A1KMT2AMEN1LMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037905-B2 Pharmaceutical use of boronic acids and esters thereof NOVO NORDISK A/S (DK) 2006-05-02 US claimed
US-20040053889-A1 Pharmaceutical use of boronic acids and esters thereof NOVO NORDISK A/S (DK) 2004-03-18 US claimed
WO-2003105860-A1 PHARMACEUTICAL USE OF BORONIC ACIDS AND ESTERS THEREOF NOVO NORDISK A/S (DK) 2003-12-24 WO claimed
US-7037905-B2 Pharmaceutical use of boronic acids and esters thereof NOVO NORDISK A/S (DK) 2006-05-02 US disclosed
US-20040053889-A1 Pharmaceutical use of boronic acids and esters thereof NOVO NORDISK A/S (DK) 2004-03-18 US disclosed
WO-2003105860-A1 PHARMACEUTICAL USE OF BORONIC ACIDS AND ESTERS THEREOF NOVO NORDISK A/S (DK) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053889-A1 Pharmaceutical use of boronic acids and esters thereof LIPE, CEL, LIPA ALDH1A1 1476/4885CYP1A2 781/4885CYP3A4 672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.